Previous close | 44.70 |
Open | 44.68 |
Bid | 44.91 x 800 |
Ask | 44.90 x 1000 |
Day's range | 44.34 - 45.37 |
52-week range | 44.34 - 69.10 |
Volume | |
Avg. volume | 16,008,464 |
Market cap | 90.9B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.10 |
Earnings date | 26 Jul 2024 |
Forward dividend & yield | 2.40 (5.37%) |
Ex-dividend date | 04 Apr 2024 |
1y target est | 54.24 |
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
PRINCETON, N.J., April 26, 2024--CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine....
A Strategic SWOT Insight into Bristol-Myers Squibb's Financials and Future